Economic Feasibility Study definition

Economic Feasibility Study. : means a comprehensive technical and economic study on the option selected to develop a mining project, and includes duly detailed assessments, notably a technical, commercial and financial assessment, required to demonstrate that mining a certain Mineral Deposit is economically and financially feasible;
Sample 1Sample 2Sample 3
Economic Feasibility Study means a feasibility study (within the meaning ascribed to that term by the Canadian Institute of Mining, Metallurgy and petroleum, as the CIM Definition Standards on Mineral Resources and Mineral Reserves adopted by CIM Council, as amended) which demonstrates the economic viability of bringing the Property into commercial production. In the event that the Optionee elects that Royce Shares be issued for all or a portion of such payment, then the number of Royce Shares required to be delivered to the Optionor shall be determined by (i) converting the US dollar amount to be so paid into Canadian dollars based on the Bank of Canada's daily noon exchange rate as of the date of completion of such economic feasibility study (or if such day is not a business day for the Bank of Canada, then on the preceding business day) and (ii) dividing the resulting Canadian dollar amount by an amount equal to the greater of: (A) the average of the closing price of the Royce Shares on the Exchange (or other stock exchange on which the common shares of Royce are principally traded) for the ten (10) Trading Days prior to the date such economic feasibility study has been approved by both parties ("Trading Day" means a day on which the Exchange (or other stock exchange on which the common shares of Royce are principally traded) is open for trading and the common shares of Royce have traded), and (B) CAD$0.05.
Sample 1Sample 2

Examples of Economic Feasibility Study in a sentence

  • Attachment 5 constitutes the Economic Feasibility Study (“Study”) adopted by the Agency and City.

  • A table detailing assumption’s as to the development timing and associated values is included in the Economic Feasibility Study located within this Plan.Expected Termination of DistrictBased on the Economic Feasibility Study located within Section 9 of this Plan, the City anticipates that the District will generate sufficient tax increment to pay all Project Costs within its allowable 20 years.Summary of FindingsAs required by Wis.

  • A table detailing assumptions as to the development timing and associated values is included in the Economic Feasibility Study located within this Plan.EXPECTED TERMINATION OF DISTRICTBased on the Economic Feasibility Study located within Section 9 of this Plan, the Village anticipates that the District will generate sufficient tax increment to pay all Project Costs within 18 of its allowable 27 years.SUMMARY OF FINDINGSAs required by Wis.

  • Attachment “3” consists of the Economic Feasibility Study (‘Study”) for the Urban Renewal Area prepared by the SURA.

  • Expected Termination of District Based on the Economic Feasibility Study located in Section 10 of this plan, this District would be expected to generate sufficient tax increments to recover all project costs by the year 2037; 10 years earlier than the 27 year maximum life of this District.

  • A discussion and listing of other possible financing mechanisms, as well as a summary of total project financing, is in the Economic Feasibility Study within this plan.Incremental ValuationThe Village projects that new land and improvements value of approximately$104,675,000 will result from the Project.

  • A tabledetailing assumption’s as to the development timing and associated values is included in the Economic Feasibility Study located within this Plan.Expected Termination of DistrictBased on the Economic Feasibility Study located within Section 9 of this Plan, the Village anticipates that the District will generate sufficient tax increment to pay all Project Costs within 27 of its allowable 27 years.Summary of FindingsAs required by Wis.

  • Expected Termination of District Based on the Economic Feasibility Study located in Section 10 of this plan, this District would be expected to generate sufficient tax increments to recover all project costs by the year 2036; 10 years earlier than the 27-year maximum life of this District.

  • The Government of the Republic of Kenya (GoK) has earmarked funds through the Development Vote for use in engaging the services of a Consultancy Firm to undertake Design Review, Updating of Resettlement Action Plan, Review of ESIA and Economic Feasibility Study Reports and Updating of Tender Documents in readiness for procurement of works for Lesseru-Kitale (B2) and Morpus – Lokichar (A1) Roads.

  • An Economic Feasibility Study is to be undertaken and submitted for any Iconic Development of a Key Site.

Related to Economic Feasibility Study

  • Feasibility Study means the evaluation and analysis of the potential of a project, which aims at supporting the process of decision-making by objectively and rationally uncovering its strengths and weaknesses, opportunities and threats, as well as identifying the resources required to carry it through and ultimately its prospects for success;

  • Interconnection Feasibility Study means either a Generation Interconnection Feasibility Study or Transmission Interconnection Feasibility Study.

  • Generation Interconnection Feasibility Study means a study conducted by the Transmission Provider (in coordination with the affected Transmission Owner(s)) in accordance with Tariff, Part IV, section 36.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Firm Transmission Feasibility Study means a study conducted by the Transmission Provider in accordance with Tariff, Part II, section 19.3 and Tariff, Part III, section 32.3.

  • Development Report means a written account of Licensee’s progress under the Development Plan having at least the information specified on Appendix B to this Agreement, and shall be sent to the address specified on Appendix B.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Development Plan has the meaning set forth in Section 3.2.

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Treatability study means a study in which a hazardous waste is subjected to a treatment process to determine: (1) Whether the waste is amenable to the treatment process, (2) what pretreatment (if any) is required, (3) the optimal process conditions needed to achieve the desired treatment, (4) the efficiency of a treatment process for a specific waste or wastes, or (5) the characteristics and volumes of residuals from a particular treatment process. Also included in this definition for the purpose of the § 261.4 (e) and (f) exemptions are liner compatibility, corrosion, and other material compatibility studies and toxicological and health effects studies. A “treatability study” is not a means to commercially treat or dispose of hazardous waste.

  • Development Area means that area to which a development plan is applicable.

  • Development Phase means the period before a vehicle type is type approved.

  • Development Site means any parcel or lot on which exists or which is intended for building development other than the following:

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Pivotal Clinical Trial means a human clinical trial in any country that is prospectively designed to generate data intended to satisfy the requirements of 21 C.F.R. § 312.21(c) (as amended) in the U.S. or a similar clinical study prescribed by a Regulatory Authority from another country, from time to time, pursuant to Applicable Law.